Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | BTK | Q06187 | 7/20 | 0.41 |
| ▸ | JAK1 | P23458 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26180336 | 0.92 | PIK3CD (0.52) | PIK3CDBTKJAK1JAK2KDM1A | |
| SCHEMBL25938760 | 0.78 | PIK3CD (0.42) | PIK3CDBTKJAK1JAK2KDM1A | |
| SCHEMBL22242695 | 0.78 | DGAT1 (0.53) | PIK3CDBTKJAK1JAK2KDM1A | |
| SCHEMBL25937197 | 0.78 | PIK3CD (0.40) | PIK3CDBTKJAK1JAK2KDM1A | |
| SCHEMBL30101652 | 0.78 | PIK3CD (0.40) | PIK3CDBTKJAK1JAK2KDM1A | |
| SCHEMBL25938752 | 0.77 | PIK3CD (0.43) | PIK3CDBTKJAK1JAK2KDM1A | |
| SCHEMBL25938789 | 0.77 | PIK3CD (0.41) | PIK3CDBTKJAK1JAK2KDM1A | |
| SCHEMBL25938780 | 0.77 | PIK3CD (0.41) | PIK3CDBTKJAK1JAK2KDM1A | |
| SCHEMBL31078611 | 0.76 | PIK3CD (0.45) | PIK3CDBTKJAK1KDM1AMAOB | |
| SCHEMBL30800446 | 0.75 | KDM1A (0.42) | PIK3CDBTKJAK1JAK2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4182320-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-115996926-A | Indole compounds as androgen receptor modulators | 尼多生物科学有限公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2022020342-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | PIK3CD 4174/4885BTK 4750/4885JAK1 3581/4885 |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | PIK3CD 4102/4885BTK 4765/4885JAK1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.